Skip to main content
Clinical Trials/ISRCTN38408464
ISRCTN38408464
Completed
未知

Pragmatic trial to assess the possibility of enhancing the effectiveness of tinnitus retraining therapy (TRT) by concomitant treatment with Ginkgo Biloba extract EGb 761® in patients with chronic tinnitus

Dr. Willmar Schwabe GmbH & Co. KG (Germany)0 sites300 target enrollmentJune 6, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Chronic Tinnitus
Sponsor
Dr. Willmar Schwabe GmbH & Co. KG (Germany)
Enrollment
300
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 6, 2014
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Eligibility Criteria

Inclusion Criteria

  • 1\. Outpatients aged \= 30 with unilateral or bilateral, chronic tinnitus (duration more than 3 months)
  • 2\. Tinnitus in the context of hearing loss, noise or mental stress
  • 3\. Tinnitus is the main complaint; other cochlear or vestibular symptoms may be present but less annoying
  • 4\. Tinnitus stage according to Biesinger 2 or higher at baseline
  • 5\. Written informed consent to participate in the clinical trial, to randomised treatment allocation and to data recording in accordance with applicable laws. Participants must be of age and they shall be able to realize the character, importance and consequences of the clinical trial and to align their volition with it.

Exclusion Criteria

  • 1\. Participation in another experimental drug trial at the same time or within the past 4 weeks before enrolment
  • 2\. Any treatments for tinnitus taken currently or within 4 weeks before randomisation
  • 3\. Acute or chronic otitis media or vestibular neuritis
  • 4\. Drug\-induced tinnitus
  • 5\. Ongoing psychiatric disorder, such as major depression, generalized anxiety disorder, schizophrenia, etc
  • Of note: Symptoms of depression or anxiety or other behavioural or psychological symptoms at sub\-syndromal level and not requiring treatment with psychotropic drugs are permitted.
  • 6\. Severe cardiac or circulatory disorder
  • \- severe (Canadian Cardiovascular Society stage IV) or unstable angina pectoris
  • \- decompensated congestive heart failure (NYHA stage IV)
  • \- uncontrolled hypertension with systolic blood pressure above 180 mmHg and/or diastolic blood pressure above 115 mmHg

Outcomes

Primary Outcomes

Not specified

Similar Trials